Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment
Novartis AG (NYSE:NVS) announced new long-term data from the ALITHIOS open-label extension study of Kesimpta (ofatumumab) for relapsing multiple sclerosis patients.…